Stay up-to-date on our latest news.
Feb 01, 2022
Clover Appoints Nicholas Jackson, Ph.D., as President of Global Research and DevelopmentJan 21, 2022
Clover's Final SPECTRA Phase 2/3 Clinical Trial Efficacy Data Is Published in The LancetJan 05, 2022
Clover Doses First Participants with Homologous Booster Dose of COVID-19 Vaccine Candidate in SPECTRAJan 05, 2022
Clover Biopharmaceuticals Announces Construction of a New R&D Center in Zhangjiang Hi-Tech Park in Pudong ShanghaiDec 09, 2021
Clover and Ascentage Pharma Announce Clinical Collaboration to Evaluate Recombinant Human TRAIL-Trimer Fusion Protein, SCB-313, in Combination with IAP Antagonist, APG-1387 for the Treatment of Peritoneal CarcinomatosisDec 07, 2021
Clover Signs COVID-19 Vaccine Supply Agreement with UNICEFNov 26, 2021
Clover's COVID-19 Vaccine Candidate Administered as Heterologous Booster in Investigator-Led Phase 2 Clinical TrialNov 18, 2021
Clover and CEPI Expand Partnership for COVID-19 Vaccine Candidate to Include Evaluation as a BoosterNov 04, 2021
Clover Biopharmaceuticals Announces Offer Price and Allotment Results of the Global OfferingSep 22, 2021
Clover's COVID-19 Vaccine Candidate Demonstrates 79% Efficacy Against Delta in Global Phase 2/3 SPECTRA Trial Dominated by Variants of Concern and Interest